eligibility_summary
Inclusion: Age ≥70 or <70 unfit, consent, ECOG 0–3, life expectancy >3 mo, CD30+ PTCL (WHO 2022), measurable lesion ≥15 mm by PET/CT, R/R after ≥1 line, no prior chidamide/brentuximab, adequate organ and marrow function, contraception. Exclusion: prior chidamide/brentuximab or recent therapy/trial <4 wks, active infection (incl. HIV/HBV/HCV), severe organ dysfunction, heart disease NYHA≥2, other cancers, VTE history, pregnant/lactating, severe immunosuppression, psych issues, unable to complete study.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT07074457 evaluates a chemo‑free regimen for CD30+ PTCL: brentuximab vedotin plus chidamide (BvC) for induction/consolidation, followed by chidamide maintenance. Brentuximab vedotin is an antibody‑drug conjugate (ADC): an anti‑CD30 monoclonal antibody linked to the microtubule‑disrupting payload MMAE. It binds CD30 on malignant T cells, is internalized, releases MMAE, and disrupts microtubules leading to G2/M arrest and apoptosis. Chidamide (tucidinostat) is an oral benzamide‑class selective histone deacetylase inhibitor (HDAC1/2/3/10). It increases histone acetylation, reprograms gene expression, induces apoptosis and cell‑cycle arrest, and can enhance antitumor immunity (e.g., boosting CTL/NK activity and antigen presentation). Targets/pathways: CD30 on PTCL cells, microtubule dynamics/cell cycle, epigenetic HDAC signaling, immune effector activation.